Manisha Balwani, MD, MS
- ASSOCIATE PROFESSOR | Genetics and Genomic Sciences
- ASSOCIATE PROFESSOR | Medicine
Specialty:Genetics and Genomics
Dr. Manisha Balwani is an Associate Professor in the Department of Genetics and Genomic Sciences and Department of Medicine at the Icahn School of Medicine at Mount Sinai. Her clinical interests include Lysosomal Storage Diseases and the Porphyrias. She is the Director of the Lysosomal Disease Program and the Comprehensive Porphyria Diagnostic and Treatment Center at Mount Sinai.
Dr. Balwani completed her medical training at the University of Bombay, followed by a Master’s in Genetics at the University of Pittsburgh. She completed her training in Internal Medicine followed by a fellowship in Medical Genetics and Clinical Biochemical Genetics. She joined the faculty of the Department of Genetics at the Icahn School of Medicine in 2006.
Her initial research efforts were focused on the natural history and genotype-phenotype correlations of Gaucher disease. She served as Principal Investigator for therapeutic clinical trials for new therapies for Gaucher disease and Lysosomal Acid Lipase deficiency. Her recent research efforts have been focused on the acute and cutaneous porphyrias. She is an investigator for the NIH supported Rare Diseases Clinical Research Network’s Porphyrias Consortium.
As an experienced physician scientist, she has been the PI of investigator-initiated and industry sponsored studies and clinical trials.
MBBS, Topiwala National Medical College
Master of Science, University of Pittsburgh - Graduate School of Public Health
Residency, Internal Medicine, North Shore Univ. Hosp. at Forest Hills
Fellowship, Medical Genetics, Mount Sinai Hospital
Fellowship, Biochemical Genetics, Mount Sinai Hospital
NIH K23 Mentored Patient-Oriented Career Development Award
Genetic Disease Foundation “Clinical Excellence Award”
NORD/Roscoe Brady Lysosomal Diseases Fellowship Award
ALN-AS1-NT-001 Natural History Study of Acute Hepatic Porphyria (AHP) Patients with Recurrent Attacks
Effect of Oral Iron Therapy on Erythrocyte Protoporphyrin Levels in the Erythropoietic Protoporphyrias
Rare Disease Registries/ Natural History Studies
All patients seen in the LSD and Porphyria Programs are welcome to participate in several industry-sponsored Registries. These are multi-center, international, observational programs that track the natural history and outcomes of patients with rare diseases including Gaucher, Fabry, MPS, Pompe disease, and Acute Hepatic Porphyria.
A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT 7117 in Subjects with Erythropoietic Protoporphyria
Premotor Signs and Symptoms of Parkinsonism in Non-Manifesting GBA Mutation Carriers
This study is actively recruiting Gaucher disease carriers or likely carriers over the age of 45 years to participate in a one-visit study. The aim of the study is to determine if a certain set of neurological tests are useful at picking up very early signs of Parkinson disease, and thus could lead to earlier diagnosis of patients. The study includes a number of tests such as questionnaires, cognitive tests, and tests examining smell and color discrimination. This study is sponsored by the NIH and Parkinson Disease Foundation and is a collaboration with Columbia Medical Center.
A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a Previous Clinical Study with ALN-AS1